TB and HIV: A Double Burden in Public Health
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.29Keywords:
tuberculosis, HIV, coinfection, diagnosis, treatmentAbstract
The TB/HIV coinfection represents a major global public health challenge, with severe implications for morbidity and mortality. The complex interaction between these two conditions significa ntly increases the risk of rapid progression for both diseases. Recent studies highlight the need for early diagnosis using advanced methods, such as rapid molecular tests, and timely initiation of antiretroviral therapy to reduce incidence and mortality. Integrated strategies, including prevention and personalized treatment, are essential, especially in the context of drug-resistant forms. Despite progress, challenges related to stigma, limited access to treatment, and drug interactions require ongoing efforts to improve clinical outcomes.
References
Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
Trăilescu A.M. Particularităţile clinico-radiologice ale tuberculozei la infectaţii hiv. Acta Medica Transilvanica. 2012; 2(2): 24-25
Афанасьев Е.И., Русских О.Е. Современные тенденции в эпидемиологии туберкулеза и ВИЧ- инфекции в мире и в Российской Федерации. РМЖ. 2021;3:24-26.
Lapshina I.S., Tsybikova E.B., Kulpesova M.A. epidemiology of tuberculosis combined with HIV infection, in the constituent entities of the Russian Federation with a low rate of tuberculosis prevalence. HIV Infection and Immunosuppressive Disorders.. 2022 Vol. 14, No. 2. P. 55–61,
Singh A, Prasad R, Balasubramanian V, Gupta N. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV AIDS (Auckl). 2020 Jan 13;12:9-31.
Pokrovsky V. Tuberculosis and HIV/AIDS: the alien and the predator. Lancet 2017 Sep 30;390(10102):1618–9.
Sergevnin VI, Tukacheva OV, Mikova OE, et al. Long- Term Dynamics of HIV-Infected Mortality and Risk Factors of the Lethal Outcome in the Presence and Absence of Concomitant Tuberculosis. Epidemiology and Vaccinal Prevention.2022;21(6): 48–58.
Hamada Y, Getahun H, Tadesse BT, et. al. HIV- associated tuberculosis. Int J STD AIDS. 2021 Aug;32(9):780-790.
Чуйкова, М.М. Эпидемиологические аспекты ВИЧ-сочетанного туберкулеза. Вестник АГИУВ, № 1-2,2015, с. 61-65.
Duarte R, Lönnroth K, Carvalho C, et. al. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology. 2018 Mar-Apr;24(2):115-119.
Matulyte E, Davidaviciene E, Kancauskiene Z, et al. The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: A thirteen-year analysis. PLoS One. 2023 Mar 23;18(3):e0282046.
Zaidi I, Sarma P, Khayyam K. Sociodemographic factors affecting knowledge levels of tuberculosis patients in New Delhi. Journal of Family Medicine and Primary Care 13(11):p 5152-5158, November. 2024
TUBERCULOZA LA ADULT. Protocol clinic național (ediția VI) PCN- 123 Chișinău, 2024.
Manina V.V., Starshinova A.A., Panteleev A.M. Tuberculosis and hiv infection: epidemic situation in russia and in the world over the past ten years, features of detection and diagnosis. HIV Infection and Immunosuppressive Disorders. 2017;9(4):7-16.
Marius Zeeb, Burcu Tepekule, Katharina Kusejko, et al. The Swiss HIV Cohort Study , Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland, Clinical Infectious Diseases, Volume 77, Issue 9, 1 November 2023, p. 1303–1311.
Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long- term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health; 2017 ; 5:e1080–9.
World Health Organization; Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: W 2018.
World Health Organization. WHO Operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020. https://apps.who.int/iris/handle/10665/331525.
Zawedde-Muyanja S. Towards tuberculosis elimination: reaching the most at-risk populations with tuberculosis preventive therapy. Lancet Glob Health. 2023 Dec;11(12):e1834-e1835.
Sodeke, Olutomi and Shah, Sarita and Pals, et.al . Lower Tuberculosis Incidence Among People with HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study. 2024.
Dlatu, N., Longo-Mbenza, B. & Apalata, T. Models of integration of TB and HIV services and factors associated with perceived quality of TB-HIV integrated service delivery in O. R Tambo District, South Africa. BMC Health Serv Res 2023 23, 804.
Global tuberculosis report 2022. Geneva: World Health organization; 2022.
Khan PY, Yates TA, Osman M, et al. Transmission of drug-resistant tuberculosis in HIV-endemic settings Lancet Infect Dis. 2019;19(3):e77-e88.
Martinez L, Woldu H, Chen C, et al. Transmission Dynamics in Tuberculosis Patients With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis of 32 Observational Studies. Clin Infect Dis.;73(9):e3446-e3455.
WHO. The global plan to Stop TB 2006–2015. Geneva, Switzerland: WHO; 2006
Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication. Policy update. Geneva: World Health Organization; 2020.
Gupta-Wright A, Fielding K, Wilson D, et al. Tuberculosis in hospitalized patients with human immunodefciency virus: clinical characteristics, mortality, and implications from the rapid urine-based screening for tuberculosis to reduce AIDS related mortality in hospitalized patients in Africa. In: Clin Infect Dis. 2020 Dec 17;71(10):2618-2626.
Geiger K., Patil A., Budhathoki C et. al. Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes. PLOS Glob Public Health. 2024 May 6;4(5):e0002714.
Pooranagangadevi N and Padmapriyadarsini C Treatment of Tuberculosis and the Drug Interactions Associated With HIV-TB Co-Infection Treatment. Front. Trop. Dis 2022. 3:834013.
Migliori GB Tiberi S. WHO drug-resistant TB guidelines 2022: what is new?. Int J Tuberc Lung Dis.; 2022 , 26: 590-591.
Walker NF, Stek C, Wasserman S, The tuberculosis- associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS 2018.;13(6):512–21.
Efsen AMW, Schultze A, Miller RF, et.al TB: HIV study in EuroCoord. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. J Infect. 2018 Jan;76(1):44-54.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
